Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency, mismatch tolerance, extension rate and/or tolerance of RT and polymerase inhibitors relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
Type:
Grant
Filed:
March 24, 2015
Date of Patent:
May 2, 2017
Assignee:
Roche Molecular Systems, Inc.
Inventors:
Keith Bauer, Thomas W. Myers, Fred Reichert, Joseph San Filippo, Rachel Shahinian, Shawn Suko
Abstract: The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function.
Type:
Grant
Filed:
January 8, 2015
Date of Patent:
April 25, 2017
Assignee:
The Regents of the University of California
Inventors:
Ehud Y. Isacoff, Richard H. Kramer, Dirk Trauner, Matthew R. Banghart, Matthew Volgraf, Pablo Ignacio Gorostiza Langa, Katharine Borges
Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
Type:
Grant
Filed:
May 21, 2015
Date of Patent:
April 18, 2017
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: Provided are a scaffold material that functions as a scaffold material for two weeks or more in vivo and causes substantially no foreign-body reaction, and a method for producing the scaffold material. Specifically, a porous scaffold material comprising collagen fibers is provided.
Abstract: The composition for tissue/cell repair facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes hydrolyzed collagen, and may include high molecular weight hydrolyzed collagen. The hydrolyzed collagen may be combined with native collagen and/or at least one other therapeutic agent. For example, the therapeutic agent may be a polysulfated glycosaminoglycan, a glucosamine salt, or mixtures thereof. The collagen may be derived from two or more different sources, and may be combined with hydrolyzed whey and/or elastin.
Abstract: Processes are provided that include additive compounds suitable for detecting the activity of an enzyme such as a lysosomal storage enzyme where the additive is a salt of oleic acid. Inclusion of a salt of oleic acid unexpectedly improves enzyme activity and reproducibility.
Abstract: The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations.
Type:
Grant
Filed:
February 28, 2012
Date of Patent:
January 31, 2017
Assignees:
THE TEXAS A&M UNIVERSITY SYSTEM, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Allison R. Ficht, Ken Carson, Cynthia Sheffield, John Herbert Waite
Abstract: The invention provides non-naturally occurring microbial organisms having a toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene pathway. The invention additionally provides methods of using such organisms to produce toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene.
Type:
Grant
Filed:
March 26, 2014
Date of Patent:
January 31, 2017
Assignee:
Genomatica, Inc.
Inventors:
Robin E. Osterhout, Anthony P. Burgard, Priti Pharkya, Mark J. Burk
Abstract: The present invention relates to recombinant N-glycosylated proteins, comprising one or more introduced N-glycosylated optimized amino acid sequence(s), nucleic acids encoding these proteins as well as corresponding vectors and host cells. In addition, the present invention is directed to the use of said proteins, nucleic acids, vectors and host cells for preparing medicaments. Furthermore, the present invention provides methods for producing said proteins.
Type:
Grant
Filed:
February 6, 2014
Date of Patent:
January 24, 2017
Assignee:
ETH ZÜRICH
Inventors:
Markus Aebi, Michael Kowarik, Umesh Ahuja
Abstract: Modified Protein A, Protein G, Protein L, or Protein A/G that lacks antibody binding activity, and methods of the modified protein's use for purifying antibodies is provided.
Abstract: The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.
Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.
Type:
Grant
Filed:
April 7, 2014
Date of Patent:
December 13, 2016
Assignee:
KUROS BIOSCIENCES AG
Inventors:
Marcel Emmerling, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner
Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.
Type:
Grant
Filed:
March 23, 2016
Date of Patent:
December 6, 2016
Assignee:
Purdue Research Foundation
Inventors:
Alyssa Panitch, John Eric Paderi, Kinam Park, Katherine Allison Stuart, Steve Higbee
Abstract: The present invention addresses the problem of providing: a two-component tissue adhesive having high adhesive strength and high biocompatibility; and a method for producing the two-component tissue adhesive. The present invention involves a two-component tissue adhesive comprising hydrophobically-modified gelatin as a first agent and a cross-linking reagent as a second agent. The hydrophobically-modified gelatin is provided with an amino group and a hydrophobic group on the side chain thereof, and the cross-linking reagent has two or more active ester groups or anhydrides within a single molecule.
Type:
Grant
Filed:
October 4, 2011
Date of Patent:
November 22, 2016
Assignee:
National Institute for Materials Science
Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Type:
Grant
Filed:
December 28, 2012
Date of Patent:
September 20, 2016
Assignee:
Halozyme, Inc.
Inventors:
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Abstract: It is an object of the present invention to provide an oriented collagen/apatite material wherein an orientation is controlled, and a method of the oriented collagen/apatite material wherein an orientation is controlled. A method of producing an orientated collagen/apatite material according to the present invention, is characterized in that the method comprises; preparing a collagen having an orientation, seeding an osteoblast or a mesenchymal stem cell to produce and fix an apatite having an orientation similar to or almost the same as a direction of an orientation of the collagen on a surface and/or inside of the collagen. Furthermore, in a preferred embodiment of above mentioned method of producing an orientated collagen/apatite material according to the present invention, is characterized in that the osteoblast is an osteoblast like cell or an osteoblast obtained from a living organism.
Abstract: The present invention discloses a composite collagen sponge and the preparation method thereof. The composite collagen sponge comprises collagen, cell growth factors, and a protecting agent, and has a water absorption capacity of more than 52 times. The preparation method includes a cation chromatographic purification step and a two-stage inactivation step consisting of organic solvent/detergent virus inactivation and dry heat virus inactivation. The composite collagen sponge obtained by the method of the present invention not only improves the safety and performance of the product in clinical applications, but also ensures the stability and the bioactivity throughout the effective life of the product.